Sino Biopharm's lung cancer treatment shows positive phase III data

Sino Biopharmaceutical Limited (HKEX: 1177) has released promising results from its Phase III clinical study evaluating benmelstobart, both with and without anlotinib, as a maintenance treatment for NSCLC patients who have not progressed following chemoradiotherapy. Presented at the 2025 ASCO Annual Meeting, the study reveals that benmelstobart combined with anlotinib significantly prolonged median progression-free survival (PFS) compared to placebo (15.1 months vs. 4.2 months), demonstrating a 51% reduction in the risk of disease progression or death. The median PFS of benmelstobart alone was also significantly prolonged. As of May 12, 2023, the study included 553 patients. The marketing application for benmelstobart with or without anlotinib has been accepted by China's Centre for Drug Evaluation (CDE) in April 2025, potentially reshaping treatment guidelines for NSCLC patients.